

[REDACTED]  
[REDACTED]  
European Medicines Agency  
Domenico Scarlattilaan 6  
1083 HS Amsterdam  
The Netherlands

08 May 2026

**Subject: Withdrawal of Veblocema (infliximab) 120 mg, solution for injection  
EMEA/H/C/006901/0000**

Dear [REDACTED],

We would like to inform you that, at this point of time, Celltrion Healthcare Hungary Kft. has taken the decision to withdraw the application for Marketing Authorization of **Veblocema (infliximab) 120 mg, solution for injection**, which was intended to be used for the following indications:

- Rheumatoid arthritis
- Crohn's disease
- Ulcerative colitis

The withdrawal is based on the following reason: due to a change in Celltrion's business strategy. This is unrelated to product quality or safety.

Celltrion reserves the right to make further submissions at a future date in the same or other therapeutic indication(s). Celltrion would like to sincerely thank the Rapporteurs, EMA, PRAC and CHMP members for the time dedicated to reviewing this application and the support provided during the procedure.

We agree for this letter to be published on the EMA website.

Yours faithfully,

[REDACTED]

[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]